{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-019765","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2022-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.481622+00:00","generated_at":"2026-06-27T15:17:13.136757+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ResMed Q2 FY2022: Revenue $894.9M (+12% YoY), GAAP EPS $1.37, non-GAAP $1.47; dividend $0.42","bullets":["Revenue $894.9M, up 12% YoY (13% constant currency); operating income $248.7M, up 12%.","GAAP diluted EPS $1.37 (up 11%); non-GAAP diluted EPS $1.47 (up 4%).","Gross margin contracted 140 bps GAAP to 56.4%; non-GAAP gross margin down 230 bps to 57.6%.","Board declared quarterly cash dividend $0.42/share, payable March 17, 2022, record date Feb 10.","CEO cited strong demand from competitor device recall, ongoing supply chain constraints."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-019765","json":"https://secwatch.observer/filing/0001193125-22-019765.json","markdown":"https://secwatch.observer/filing/0001193125-22-019765.md","text":"https://secwatch.observer/filing/0001193125-22-019765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312522019765/0001193125-22-019765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312522019765/d477629d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:17:13.136757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}